t.spot covid
HIGHLIGHTS
- •
TSPOT.COVID is an ELISpot interferon gamma-release assay for SARS-CoV-2
- •
TSPOT.COVID identifies a T cell response to SARS-CoV-2 spike S1 and N peptides
- •
2–8 weeks post SARS-CoV-2 diagnosis TSPOT.COVID detected 98% of infections
- •
In comparison, immunoglobulin G (IgG) serology detected 83% of infections in the same period
- •
Cellular immune response activated sooner and lasted longer than antibodies
Abstract
Objective
Methods
Results
Conclusion
Introduction
). The T-SPOT.COVID test was developed to identify the presence of SARS-CoV-2-responsive T cells.
;
;
). T cells can provide immune memory lasting for months (
) and perhaps years, as suggested by the discovery of T cells to the SARS-CoV-1 coronavirus 17 years after infection (
). T cells may act independently of antibodies to control a SARS-CoV-2 infection, as shown by the recovery of COVID-19 patients who lack detectable antibodies but have SARS-CoV-2-responsive T cells (
;
). T cells also show reactivity to numerous SARS-CoV-2 epitopes, so have the potential to protect against many SARS-CoV-2 variants (
;
). T cell-based assays can probe the longevity of an immune response following a SARS-CoV-2 infection or vaccination (
;
;
). These various roles suggest that a T cell assay can be a key contributor to SARS-CoV-2 investigations.
;
). The T-SPOT.COVID ELISpot methodology is performed in many laboratories and offers a standardized comparison of T cell immunity among participants. In addition, ELISpot assays normalize the number of peripheral blood mononuclear cells (PBMCs), thus maintaining test effectiveness in participants with lymphopenia, a commonly reported condition in many COVID-19 patients (
) and immunosuppressed people.
Materials and Methods
2.1 Participant recruitment
). Participants in the confirmed-infection group were recruited from asymptomatic and symptomatic patients who had had a positive SARS-CoV-2 NAAT result within the past 9 months. The date of the first positive NAAT result was considered the date of diagnosis of SARS-CoV-2 infection. Blood was drawn for Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) anti-N IgG serology and T-SPOT.COVID tests between 0 to 249 days after diagnosis.
2.2 T-SPOT.COVID test
COVID-19 Spike Antigen |
|||
30-2018 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
COVID-19 Spike Antigen |
|||
30-2019 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
SARS & COVID-19 coronavirus |
|||
3862 | Virostat | each | EUR 330 |
Description: nucleoprotein |
SARS & COVID-19 coronavirus |
|||
3863 | Virostat | each | EUR 330 |
Description: nucleoprotein |
SARS & COVID-19 coronavirus |
|||
3864 | Virostat | each | EUR 330 |
Description: nucleoprotein |
COVID-19 S Protein / (GFP)– (6His) VLP COVID-19 S Protein / (GFP)– (6His) VLP |
|||
VLP001 | GenTarget | 1x108 VP/ml x 200ul | EUR 455 |
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with GFP genomic material. Particles were concentrated and provided in PBS solution |
COVID-19 Nucleocapsid protein |
|||
30-2005 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant antigen |
COVID-19 Nucleocapsid protein |
|||
30-2006 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant Antigen |
COVID-19 Nucleocapsid antigen |
|||
30-2020 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Nucleocapsid recombinant protein |
COVID-19 Nucleocapsid antigen |
|||
30-2021 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Nucleocapsid recombinant protein |
STAT-NAT COVID-19 B |
|||
BSV-qPCR-12 | BioServUK | 24 tests | EUR 316 |
Description: STAT-NAT COVID-19 B |
STAT-NAT COVID-19 HK |
|||
BSV-qPCR-13 | BioServUK | 24 tests | EUR 316 |
Description: STAT-NAT COVID-19 HK |
COVID-19 Nucleoprotein antibody |
|||
10-2890 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
COVID-19 Nucleoprotein antibody |
|||
10-2891 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
COVID-19 Nucleoprotein antibody |
|||
10-2894 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
STAT-NAT COVID-19 MULTI |
|||
BSV-qPCR-11 | BioServUK | 96 tests | EUR 758 |
Description: STAT-NAT COVID-19 MULTI |
COVID-19 IgG & IgM antibody |
|||
GEN-50001-50tests | Ring Bio | 50 tests | EUR 388.8 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
COVID-19 Antigen Rapid Test |
|||
ICOV-802H | Hangzhou AllTest Biotech | 25 Tests | EUR 12.5 |
Coronavirus (COVID-19) CE IVD |
|||
PRD-Z-Path-COVID-19-CE | BioServUK | 96 tests | EUR 2539 |
Description: Coronavirus (COVID-19) CE IVD |
COVID-19 Antigen Detection Kit |
|||
BSV-G61RHA20 | BioServUK | 20 tests | EUR 500 |
Description: COVID-19 Antigen Detection Kit |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-48T | Biomatik Corporation | 48T | EUR 400.4 |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-5x96T | Biomatik Corporation | 5x96T | EUR 2717 |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-96T | Biomatik Corporation | 96T | EUR 572 |
COVID-19 (SARS-CoV-2) IgG |
|||
DECOV1901 | Demeditec Diagnostics | 96 | EUR 232 |
COVID-19 (SARS-CoV-2) IgA |
|||
DECOV1902 | Demeditec Diagnostics | 96 | EUR 232 |
Nadal COVID-19 IgG/IgM Test |
|||
BSV-243001N-10 | BioServUK | 10 tests | EUR 316 |
Description: Nadal COVID-19 IgG/IgM Test |
COVID-19 Envelope Protein Antibody |
|||
E38PA9967 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
COVID-19 S Protein -(6His) VLP |
|||
VLP003 | GenTarget | 1x108 VP/ml x 200ul | EUR 455 |
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with Null non-sense sequence. Particles were concentrated and provided in PBS solution |
COVID-19 Spike glycoprotein Antibody |
|||
E38PA9966 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
GA COVID-19 Rapid Antigen Test |
|||
BSV-3980 | BioServUK | 20 tests | EUR 500 |
Description: GA COVID-19 Rapid Antigen Test |
COVID-19 Nucleocapsid Protein Antibody |
|||
E38PA9965 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
COVID-19 Nucleocapsid recombinant antigen |
|||
00221-V | Virogen | 1 MG | EUR 850 |
COVID-19 Nucleocapsid recombinant antigen |
|||
00221-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Nucleocapsid recombinant antigen |
Biocredit Covid-19 Ag Detection Kit |
|||
G61RHA20 | RapiGEN | 20 test cards (pkg) | EUR 114 |